GlassScriptPhysician profile
Miguel A Ramos
NPI 1669400859
$3,338.35
in general payments reported to CMS, 2019-2025
23 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $348 · 2021: $504 · 2022: $434 · 2023: $430 · 2024: $645 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.23 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $427.43 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $248.52 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.93 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $186.27 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $171.14 | 2019-2023 | Veklury |
| Ironwood Pharmaceuticals, INC | $133.10 | 2019-2023 | Linzess |
| Janssen Biotech, INC. | $130.01 | 2022-2023 | Stelara |
| Novo Nordisk INC | $120.83 | 2025 | Wegovy |
| Boston Scientific Corporation | $118.58 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.97 | 2019-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $74.58 | 2024 | |
| Davol INC. | $73.67 | 2021 | |
| Genzyme Corporation | $67.95 | 2024-2025 | |
| Medtronic, INC. | $58.03 | 2021-2025 | Pillcam |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $41.46 | 2021-2023 | Zeposia |
| Vivus LLC | $41.26 | 2022 | |
| Qol Medical, LLC | $37.61 | 2024 | Sucraid |
| Axonics, INC. | $25.76 | 2024 | Axonics |
| Olympus America INC. | $18.20 | 2024 | Endoclot Phs |
| Pfizer INC. | $13.36 | 2020 | |
| Enterra Medical, INC. | $12.57 | 2022 | |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.